Watermark

AdvanTIG-205

Completed

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

AdvanTIG-205

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

EudraCT Number Info icon SVG graphic used for tooltips or additional information.

2021-001075-17

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20212782

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary